The paucity of therapeutic choices is a reality often acknowledged by the US Food and Drug Administration (FDA) as it reviews applications for new medical …
Just months after wrapping up the Alexion acquisition, AstraZeneca is beefing up its newly established rare disease portfolio with a collaboration with Ionis Pharmaceuticals, targeting …
Amid its push to grow around the globe in oncology, rare diseases and neuroscience, Ipsen has poached a Novartis veteran to head up its international …
Journal For Clinical Studies has a distinguished editorial advisory board providing the best guidelines for global clinical trials. Your resource for Multisite Studies and emerging markets.
